Protocol for genome-scale in vivo CRISPR screening to study protection of beta cells under autoimmunity in a type 1 diabetes mouse model
Files
If you need an accessible version of this item, please email your request to digschol@iu.edu so that they may create one and provide it to you.
Date
2023
Language
American English
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Elsevier
Abstract
Autoimmunity-induced pancreatic beta cell failure is the main characteristic of type 1 diabetes (T1D). Here, we describe a protocol for genome-scale in vivo CRISPR-Cas9 screening for use in a mouse model of T1D. Using a non-obese-diabetic-derived mouse beta cell line, NIT-1, and a genome-wide CRISPR-Cas9 knockout library (GeCKO-v2), we describe how to identify genes that confer resistance to autoimmune killing. This protocol can be applied in other mouse models of autoimmunity. For complete details on the use and execution of this protocol, please refer to Cai et al. (2020).
Description
Keywords
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Li J, Lee YC, Iessi IL, Wu C, Yi P, Cai EP. Protocol for genome-scale in vivo CRISPR screening to study protection of beta cells under autoimmunity in a type 1 diabetes mouse model [published online ahead of print, 2023 Mar 13]. STAR Protoc. 2023;4(2):102155. doi:10.1016/j.xpro.2023.102155
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
STAR Protocols
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
Version
Final published version